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Introduction
Multiple sclerosis (MS) is a chronic neuroinflammatory immunemediated disease of the central nervous system (CNS) with unknown etiology and variable clinical profile 1 . It has demonstrated that production of cytokines by infiltrating inflammatory cells and resident cells in the brain is involved in directing and regulating the immune response and also mediating of tissue damage 2 . Cytokines and their receptors are important factors of immune system and play a role in pathologic hallmarks of MS 3, 4 . IL-23 is a heterodimeric cytokine which comprises two subunits including p19 and a common p40 subunit that shares with IL-12 5 . It has demonstrated that a subset of inflammatory macrophages and dendritic cells express receptor complex of IL-23 6 . IL-23 is constructed mainly by activation of dendritic cells (DCs) and phagocytic cells, preferentially activates memory rather than naive T cells, stimulates of INF-ƴ secretion from T cells and is involved in Th1-type immune responses 5 . It has found that IL-23 upon antigen-specific stimulation contribute to development and expansion of activated CD4
+ cells that produce IL-17, IL-17F, IL-6, and TNF and plays a critical role in autoimmune inflammation 7 . Several studies suggest that the family members of IL-17 play an important role in autoimmune and inflammatory diseases Th17 cells and IL-23 are  essential for the induction of experimental models of  multiple sclerosis and increased expression of IL-23 and  IL-17 has been reported in patients with MS   7, 10-14 . Active and chronic active lesions in the multiple sclerosis have shown highly expression of proinflammatory cytokine IL-23 and activated macrophages/ microglia and mature DCs have proposed as cellular sources of IL-23p19 in these lesions 12 . Production of p40 subunit of IL-23 and in vitro production of IL-23 by activated microglia support from this hypothesis that production of bioactive IL-23 plays an important role in the pathogenesis of MS 12, 15 . IL-23 by modulation of the interaction of Microglia-T cell in multiple sclerosis may impact on the local inflammatory response in the brain 12 . It has suggested that correlation between expression of IL-23 and inflammatory and demyelinating lesions in MS that probably through recruitment and activation of some essential inflammatory cells that are responsible for chronic inflammation plays a crucial role in the immunopathogenesis of multiple sclerosis
.
Targeting of IL-23 or IL-23-receptor has suggested as a probably promising therapeutic approach for a range of inflammatory autoimmune diseases 10 . In the present study, we examined mRNA expression level of IL-23 using RealTime PCR technique in the peripheral blood of patients with multiple sclerosis and healthy control groups. We demonstrate herein that a high mRNA expression pattern of IL-23 in peripheral blood is a feature of MS.
Material and methods
Fifteenth patients with clinically definite MS (9 women, 6 men) from the MS Clinic of Kashani University Hospital at the Isfahan University of Medical Sciences and 15 healthy control subjects (8 females, 7 males) were included in this study. Severity of illness was evaluated using expanded disability status scale (EDSS) 16 and disease type was defined as relapsing-remitting (RR), primary progressive (PP) or secondary progressive (SP). All of patients were diagnosed according to the revised McDonald criteria 17 , and MS clinical forms were determined according to the classification of Lublin & Reingold
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.Ten patients (66.7%) suffered from relapsing-remitting MS; three patients (20%) were in the primary progressive phase of the disease and two patients (13.3%) were in the secondary progressive phase of the disease. None of the Patients was received any immunomodulatory drugs such as methylprednisolone or interferon-(IFN-β) for at least 4 weeks prior to inclusion, and had not had an acute exacerbation prior to inclusion. The Ethical Committee on Human Research, Isfahan University of Medical Sciences approved protocol of study and written informed consent was obtained from all participating prior to entering the study. Patients with infection diseases or other autoimmune diseases, cardiovascular or renal disease, cancer and blood systemic disorders were excluded from study. Clinical and demographic features of participants have been summarized in Table 1 .
Venous blood samples (5 ml) were collected from both control and patient groups and Total RNA was extracted from whole blood using using High pure RNA isolation kit according to the manufacturer's instructions (Qiagen, USA). Spectrophotometry showed optical density ratio of 260 nm to 280 nm (1.8−2.1) for extracted RNA confirming purity and quantity of extracted RNA in optimal range. Complementary DNA (cDNA) was synthesized with oligo (dT) primer using a reverse transcription ki (Fermentaz, Germany). IL-23 mRNA expression was quantified by realtime PCR using Prime Q-Mastermix reagent kit (2X, Realtime PCR with SYBR Green I) (GenetBio, republic of Korea). All reactions were performed at triplicate. The relative gene expression of the IL-23 was normalized to GAPDH as the reference gene.
Statistical analysis
The normal distribution of clinical variables and gene expression data were checked using Kolmogorov-Smirnov test. Two-tailed t-test, chi-square test, Kruskal-Wallis test and Mann-Whitney test were used for comparison of study groups by SPSS20. The relationships between IL-23 mRNA and clinical characteristics were examined with Pearson's correlation coefficient. p<0.05 was considered as statistical significant.
Results
Demographic characteristics didn't show significant difference between two groups. Two-tailed t-test showed significantly higher relative levels of IL-23 mRNA (7.98 ±1.61, t=-16.693, p<0.001) in peripheral blood of patients with multiple sclerosis in compared to healthy controls ( Figure 1 ). We didn't find significant correlation between mRNA expressions of IL-23 and severity of illness in MS patients (rs=-0.065, p=0.817). A significant negative correlation was found between severity of illness and age in patients with MS (rs=-0.731, p=0.002). Multiple sclerosis 
patients showed no significant correlation between age and IL-23 mRNA level (rs=0.148, p=0.599). Two-tailed t-test revealed no significant difference in the mRNA expression level of IL-23 between male and female (p =0.493).
A Kruskal-Wallis test showed that there was a statistically significant difference in the relative levels of IL-23 mRNA between three groups (χ 2 =7.33, df=2, p=0.026).
Mann-Whitney test showed significantly higher relative levels of IL-23 mRNA in peripheral blood of RRMS patients in compared to PPMS patients (Z=-2.20, p=0.028). Relative levels of IL-23 mRNA in peripheral blood didn't show a significant difference between RRMS patients and SPMS patients (Z=-1.937, p=0.053) as well as between PPMS patients and SPMS patients (Z=-0.577, p=0.564).
Discussion
In the present study we found higher mRNA expression of IL-23 gene in peripheral blood of MS patients in compared to control subjects. Our results are in agreement with findings reported by several studies indicating increased plasma and mRNA expression levels of IL-23 in MS patients 12, 14, 19, 20 . It has found that MS patients show increased secreted levels of IL-23 from monocyte-derived Dendritic Cells (DCs) and also mRNA overexpression of both IL-23p19 and IL-12/23p40 . Collected data in mice confirm that in the development of EAE the IL-23 plays an important role rather than IL-12 10, 29 .It has found that therapeutic effect of IL-23 induced by anti-IL-23p19 inhibited relapse of disease during active EAE
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. Some mechanisms of action have suggested for anti-IL-23p19 therapeutic inhibition of EAE relapse including inhibition of epitope spreading to additional encephalitogenic epitopes such as proteolipid protein178-191 (PLP178-191) and recruitment of newly activated pathogenic T cells and reduction of the number of inflammatory myeloid cells invading the CNS and diminishing the levels of monokines secreted by macrophage and dendritic cells 26 .It has suggested that reduced number of inflammatory myeloid cells that invade the CNS and diminish the concentration of monokines produced by dendritic cells and macrophage such as IL-1, IL-6, and TNF implicate in the mechanism of action of anti-IL-23p19 therapy 26 . The pathological hallmarks of EAE and MS have attributed to this myeloid cell invasion and production of proinflammatory factors 26 . It has proposed that the inhibition of IL-23 using designing drugs that target the IL-23p19 or IL-23 receptor might be a novel and promising therapeutic strategy in treatment of autoimmune inflammatory diseases such as multiple sclerosis 25, 26 . The main finding of our study is that untreated MS patients have increased expression of IL-23 mRNA in the peripheral blood that is agreement with findings reported by previous studies 12, 14, 19, 20 . Most of these studies measured the common IL-12p40 subunit shared by IL-12 and IL-23. It has demonstrated that patients with both RR and SP MS show overexpression of IL-23p19 and p40, but not IL-12p35 mRNA and also increased IL-23 production compared to healthy subjects 14 . Accordingly, increased mRNA levels of IL-23 have been found in MS 12, 13 . It has demonstrated that IL-23 deficient mice are resistant to EAE animal models and untreated MS patients have shown increased levels of IL-23 mRNA that treatment with IFN-β result in suppression of IL-23 mRNA 10, 19 . In conclusion, we have presented findings that peripheral blood from patients with multiple sclerosis exhibit higher mRNA expression of proinflammatory cytokine IL-23 when compared to healthy controls. These findings support the role of IL-23 in the pathogenesis of multiple sclerosis as an inflammatory autoimmune disease and may have implications as a specific peripheral marker for MS.
